Product Development

RA readout drives Aclaris’ first big gain since shifting focus to innovative immunology pipeline

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it